Publication stageIn Press Journal Pre-Proof
Disclosure Statement of Conflict of Interest:
MCB has no disclosures. JST has research funding from Blue Note Therapeutics to MGH. MMK has served as a compensated consultant for AstraZeneca, Sanofi, BMS, and Janssen Oncology and received loyalties from Elsevier, not related to the current case. LLR has received honoraria from PeerView, Medscape, Clinical Care Options, consulting honoraria from Abbvie, Personal Genome Diagnostics, Bristol Myers Squibb, Loxo Oncology at Lilly, Amgen, Merck, AstraZeneca, Sanofi-Genzyme, and EMD Serono. IDJ has received honoraria from Foundation Medicine, Creative Education Concepts, OncLive, ASCO Post, DAVA Oncology, Medscape, Total Health, Triptych Health Partners, and Aptitude Health, American Lung Association, consulting fees from AstraZeneca, Boehringer Ingelheim, Bayer, BostonGene, Bristol Myers Squibb, Catalyst, Genentech, Janssen, Novocure, Pfizer, Sanofi-Genzyme, Syros, and Xcovery, research support from Array, Genentech, Novartis, Pfizer, and Guardant Health, and travel support from Array and Pfizer.
MCB: Writing - original draft and review and editing. JST: Writing - review and editing. MMK: Writing - review and editing, resources. LLR: Writing - review and editing, resources. IDJ: Conceptualization, writing - original draft and review and editing.
User licenseCreative Commons Attribution – NonCommercial – NoDerivs (CC BY-NC-ND 4.0) |
For non-commercial purposes:
- Read, print & download
- Redistribute or republish the final article
- Text & data mine
- Translate the article (private use only, not for distribution)
- Reuse portions or extracts from the article in other works
- Sell or re-use for commercial purposes
- Distribute translations or adaptations of the article
Elsevier's open access license policy